Anavar (Oxandrolone): Why It's Called "Mild" and What the Real Risks Are

Anavar is the best-known brand name for oxandrolone, and the oral steroid most often described as "mild and safe" in training circles. The pharmacology is considerably more complicated: it is 17-alpha-alkylated, the FDA withdrew its approval in 2023 over safety and efficacy concerns, and it is among the harshest compounds on cholesterol. This guide covers what the research actually shows — with no doses or usage protocols.

What is Anavar?

Anavar is the brand name for oxandrolone, an oral anabolic steroid developed in 1964. Structurally it derives from dihydrotestosterone (DHT), with an oxygen atom replacing a carbon in the A ring, plus 17-alpha-alkylation that lets it survive first-pass liver metabolism and work orally.

Because it derives from DHT it does not aromatise to oestrogen, so it causes no gynecomastia and little noticeable water retention — precisely the traits its reputation as a "clean" compound is built on. But the absence of visible side effects is one thing; the compound's internal safety is another entirely.

Medical use and the approval withdrawal

Oxandrolone was used medically as adjunct therapy to promote weight gain after major surgery, chronic infection and severe trauma, to relieve bone pain in osteoporosis, and to offset muscle catabolism from long-term corticosteroids. Its strongest data came from children with severe burns, where controlled studies showed improvements in lean mass, muscle strength and bone mineral content, alongside mild rises in liver transaminases and reversible sexual changes that required close monitoring.

Even so, the FDA notified licence holders in 2022 that the product should be removed from the market, and approval was withdrawn in 2023, citing a lack of demonstrated efficacy together with extensive safety warnings: peliosis hepatis, sometimes with liver failure and intra-abdominal haemorrhage; liver cell tumours, sometimes fatal; and blood lipid changes associated with atherosclerosis.

That isn't an administrative footnote: the compound marketed in gyms as "the safest one" is the same compound a regulator decided had risks outweighing its benefits.

How it works

Oxandrolone binds androgen receptors, increasing protein synthesis and improving nitrogen balance. It has one additional, well-studied property: antagonising cortisol signalling through the androgen receptor, reducing the muscle catabolism driven by stress hormones — which is exactly why it helped in burn and wasting patients.

As a DHT derivative it doesn't convert to oestrogen and isn't meaningfully 5-alpha reduced, so its effect tends toward muscle hardness with little water retention. The same caveat still applies: anabolic and androgenic actions are linked, and there is no such thing as a purely anabolic compound with no cost.

The liver: where the problem actually sits

The 17-alpha-alkylation that makes it orally active is the same feature that strains the liver. Oxandrolone is genuinely considered less hepatotoxic than other orals like methandienone and stanozolol, and the burn studies recorded only mild, reversible transaminase rises — but "less" is not "safe."

What the boxed warning states plainly:

• Peliosis hepatis: blood-filled cysts in the liver that may go unrecognised until liver failure or intra-abdominal haemorrhage develops.
• Liver cell tumours: usually benign and androgen-dependent, but fatal malignant tumours have been reported.
• Cholestatic hepatitis and jaundice: can occur with alkylated androgens at relatively low doses.

These lesions usually regress when the drug is withdrawn, which is exactly why liver function monitoring and immediate discontinuation on jaundice or severe abdominal pain are part of the label.

Cholesterol: the worst of it

If one thing makes calling Anavar "mild" misleading, it's the lipid effect. Orally alkylated androgens sharply lower HDL and raise LDL, and oxandrolone is among the most aggressive in this respect — HDL can fall substantially within a few weeks.

That isn't a cosmetic number on a lab report: this lipid pattern is directly tied to accelerated atherosclerosis and increased cardiac risk, and it is one of the explicit grounds for the FDA's decision. Reduced glucose tolerance is documented with this class as well.

The upshot: the absence of gynecomastia and bloating makes the compound look "clean" in the mirror, while the damage accumulates in the lipid profile and the arterial wall, where nobody sees it.

Hormonal suppression: the second myth

It's widely claimed that Anavar "doesn't suppress because it's mild." In reality oxandrolone lowers LH and FSH and reduces endogenous testosterone production, and the paediatric burn studies documented "reversible sexual changes" during treatment, with fertility effects noted among the label warnings.

The degree of suppression depends on dose and duration, but its existence isn't in question. In practice it shows up after stopping as fatigue, reduced libido and loss of some of the gains — symptoms wrongly attributed to "the drug wearing off" when they are temporary hypogonadism that needs assessment with blood work.

Use in women and virilisation

Anavar is marketed as "the women's steroid" for its relatively low androgenicity and lack of aromatisation. But low androgenicity is relative, not absolute, and virilisation is documented: voice deepening, facial and body hair growth, clitoral enlargement, and menstrual disruption.

The decisive point is that some of these don't reverse after stopping — voice changes and clitoral enlargement in particular can be permanent. The drug also causes embryotoxicity and masculinisation of female offspring in animal studies, so it is absolutely contraindicated in pregnancy.

The rest of the side effects

• Fluid retention and oedema: a serious complication in patients with cardiac, renal or hepatic disease.
• Raised blood pressure and increased cardiac load.
• Hypercalcaemia in breast cancer patients, by stimulating osteolysis.
• Prostate: increased risk of hypertrophy and carcinoma in older patients per the label warnings.
• Acne and oilier skin, and accelerated baldness in those genetically predisposed.
• Mood swings and irritability, with low mood on stopping.
• Significant drug interactions: it markedly potentiates warfarin, raising bleeding risk and requiring dose reduction with more frequent INR monitoring, and it potentiates glucose-lowering drugs, increasing hypoglycaemia risk.
• In children: premature epiphyseal closure affecting final height.

Contraindications: prostate or male breast cancer, hypercalcaemia, nephrotic syndrome, severe liver disease, pregnancy and breastfeeding.

The most counterfeited compound on the market

Since the US approval withdrawal, oxandrolone is no longer commercially available there except through compounding pharmacies on a patient-specific prescription. The result is that most of what sells as "Anavar" on the grey market isn't oxandrolone at all.

Independent testing of grey-market samples has repeatedly found tablets containing cheaper compounds — stanozolol, methandienone, even dexamethasone — or far less active ingredient than claimed, or none at all. Because oxandrolone raw material is among the most expensive, the economic incentive to counterfeit it is the highest of any steroid.

In practice: someone who believes they're taking a "mild" compound may be taking one many times more hepatotoxic, with no way of knowing.

The stacking question

"Stacking" means using more than one hormonal compound at once. We cover it as a phenomenon whose risks need to be understood — you won't find doses, combinations or cycle schedules on Vinnofit.

Anavar is usually presented as a "mild addition" to other compounds, and that's exactly where the problem lies: every added compound pushes the lipid profile in the same direction, and Anavar is among the harshest on HDL. The "mild" one adds a heavy effect in the one area you can't see in the mirror.

• Hepatic accumulation: combining an alkylated compound with another alkylated one, or with other liver-affecting drugs, multiplies the strain.
• Lipid accumulation: HDL falls from every source at once.
• Deeper, longer suppression as compounds and duration increase.
• Attribution becomes impossible when a problem appears, turning medical management into guesswork.
• No clinical trials on combinations: what circulates is personal experience, not controlled studies, at doses many times medical ones.

And for anyone with a confirmed hormone deficiency: the right path is diagnosis and supervised treatment, not one oral compound added to another.

Detection in doping tests

Oxandrolone is prohibited in and out of competition under the World Anti-Doping Agency list. It is detected through urinary metabolites, and the detection window runs to weeks after the last dose despite its short half-life — considerably longer than many users assume from how quickly they feel it clear.

Legal status

In Oman and across the GCC, oxandrolone is a scheduled prescription-only substance; possessing, selling or importing it without a prescription is a legal offence. In the United States it is Schedule III, and no commercially approved product remains there since the withdrawal.

Common myths

"Anavar is mild and safe": "mild" here only means no gynecomastia and no bloating. Cholesterol, liver and suppression are not mild, and the FDA's withdrawal rests on exactly those three.

"It doesn't suppress": it does, to a degree set by dose and duration, with sexual changes documented even in supervised medical use.

"It's liver-safe because it's less toxic than others": the boxed warning lists peliosis hepatis and liver tumours, and notes cholestatic hepatitis can occur at relatively low doses.

"Ideal for women": virilisation is documented, and some of it — voice deepening, clitoral enlargement — is permanent.

"What I bought is real Anavar": it's the most counterfeited compound there is, given expensive raw material and withdrawal from the legitimate market.

Related reading

Frequently asked questions

Sources

• Oxandrolone tablets — FDA label with boxed warning
• Oxandrolone — AHFS Drug Information monograph (Drugs.com)
• Btaiche & Miller — Oxandrolone in Pediatric Patients with Severe Thermal Burn Injury (2008)
• Oxandrolone — pharmacology, regulatory history and withdrawal